Cargando…
Assessment of the feed additive consisting of Enterococcus lactis DSM 7134 (Bonvital®) for chickens reared for laying and minor poultry species other than those used for laying for the renewal of its authorisation (Lactosan GmbH & Co.KG)
Bonvital® is the trade name for a feed additive currently authorised for use in piglets, pigs for fattening, sows, chickens for fattening, laying hens, chickens reared for laying and minor poultry species (other than those used for laying). This opinion concerns the renewal of the authorisation of B...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598614/ https://www.ncbi.nlm.nih.gov/pubmed/37886613 http://dx.doi.org/10.2903/j.efsa.2023.8351 |
Sumario: | Bonvital® is the trade name for a feed additive currently authorised for use in piglets, pigs for fattening, sows, chickens for fattening, laying hens, chickens reared for laying and minor poultry species (other than those used for laying). This opinion concerns the renewal of the authorisation of Bonvital® as a zootechnical additive for chickens reared for laying and minor poultry species other than those used for laying. The active agent of Bonvital® was originally identified as Enterococcus faecium. During the current assessment, the strain was reassigned to Enterococcus lactis. The applicant provided evidence that the additive currently on the market complies with the existing terms of authorisation. There is no new evidence that would lead the FEEDAP Panel to reconsider its previous conclusions. Thus, the Panel concluded that the additive remains safe for the target species, consumers and the environment under the authorised conditions of use. Bonvital® was found to be non‐irritant to skin and eyes, but a potential respiratory sensitiser. No conclusions could be drawn on the skin sensitisation potential of the additive. There is no need to assess the efficacy of Bonvital® in the context of the renewal of the authorisation. |
---|